FDA approves ‘precision medicine’ drug for different cancers with the same mutation

The Food and Drug Administration normally approves drugs based on what type of cancer they treat, such as lung or skin cancer. The new drug, called Vitrakvi, is the second treatment to receive FDA clearance based on a biomarker found in an array of cancers. This “site-agnostic” approach means the approval is based on a […]

Shares
|ShareTweet